Ebos Group Ltd

EBO: XNZE (NZL)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|.vLOCK|Dr$LPLOCK|K!^@&xy#

Ebos Group Earnings: Disappointing Outlook as Costs Step Up

Ebos grew underlying fiscal 2025 EBITDA by 8%, with 18% sales growth in higher-margin medical technology. However, fiscal 2026 guidance implies just 5% organic EBITDA growth due to higher costs and softness in discretionary pet products. Shares reacted negatively, down 15%.

Sponsor Center